SG11201506479TA - Substituted xanthines and methods of use thereof - Google Patents

Substituted xanthines and methods of use thereof

Info

Publication number: SG11201506479TA
Authority: SG; Singapore
Prior art keywords: methods; substituted xanthines; xanthines; substituted
Prior art date: 2013-03-15

Application number

SG11201506479TA

Other languages

English (en)

Inventor

Bertrand Chenard

Randall Gallaschun

Original Assignee

Hydra Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-14

Publication date

2015-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201506479T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-14 Application filed by Hydra Biosciences Inc filed Critical Hydra Biosciences Inc

2015-09-29 Publication of SG11201506479TA publication Critical patent/SG11201506479TA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epidemiology (AREA)
Thiazole And Isothizaole Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Silver Salt Photography Or Processing Solution Therefor (AREA)

SG11201506479TA 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof SG11201506479TA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361789724P	2013-03-15	2013-03-15
PCT/US2014/027920 WO2014143799A2 (en)	2013-03-15	2014-03-14	Substituted xanthines and methods of use thereof

Publications (1)

Publication Number	Publication Date
SG11201506479TA true SG11201506479TA (en)	2015-09-29

Family

ID=50680155

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201506479TA SG11201506479TA (en)	2013-03-15	2014-03-14	Substituted xanthines and methods of use thereof

Country Status (31)

Country	Link
US (7)	US9359359B2 (uk)
EP (1)	EP2970303B3 (uk)
JP (1)	JP6360149B2 (uk)
KR (1)	KR102227629B1 (uk)
CN (2)	CN107082782B (uk)
AU (1)	AU2014228206C1 (uk)
CA (1)	CA2899646C (uk)
CL (1)	CL2015002738A1 (uk)
CY (1)	CY1119042T1 (uk)
DK (1)	DK2970303T6 (uk)
EA (1)	EA028815B1 (uk)
ES (1)	ES2636835T7 (uk)
HR (1)	HRP20170840T4 (uk)
HU (1)	HUE033528T4 (uk)
IL (1)	IL240216B (uk)
LT (1)	LT2970303T (uk)
MX (1)	MX370372B (uk)
MY (1)	MY189912A (uk)
NZ (1)	NZ711718A (uk)
PE (1)	PE20151779A1 (uk)
PH (1)	PH12015502141B1 (uk)
PL (1)	PL2970303T6 (uk)
PT (1)	PT2970303T (uk)
RS (1)	RS56066B2 (uk)
SG (1)	SG11201506479TA (uk)
SI (1)	SI2970303T1 (uk)
TW (1)	TWI609867B (uk)
UA (1)	UA117470C2 (uk)
UY (1)	UY35488A (uk)
WO (1)	WO2014143799A2 (uk)
ZA (1)	ZA201505414B (uk)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8173750B2 (en)	2009-04-23	2012-05-08	ATRP Solutions, Inc.	Star macromolecules for personal and home care
PE20151779A1 (es)	2013-03-15	2015-11-20	Hydra Biosciences Inc	Xantinas sustituidas y metodos de uso de las mismas
EP3180342B1 (en) *	2014-08-11	2019-06-26	Hydra Biosciences, Inc.	Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
WO2016159747A1 (en)	2015-03-27	2016-10-06	Latvian Institute Of Organic Synthesis	Ethynylxanthines, preparation and use as calcium ion channel modulators
CA2989161C (en)	2015-03-27	2022-03-01	Latvian Institute Of Organic Synthesis	Ethynylxanthines, preparation and use for cancer treatment
GB2553685B (en)	2015-03-27	2020-06-10	Latvian Inst Organic Synthesis	Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis
KR20170133493A (ko) *	2015-04-08	2017-12-05	루이스 앤드 클라크 파마슈티컬스, 인코포레이티드	A2b 길항제로서 크산틴-치환된 알키닐 카르바메이트/리버스 카르바메이트
CN107118586A (zh) *	2016-02-24	2017-09-01	中国科学技术大学	含氮杂环基取代的烯类化合物的用途
GB201702160D0 (en) *	2017-02-09	2017-03-29	Univ Leeds Innovations Ltd	Inhibitors for use in therapy
US11666577B2 (en) *	2017-02-28	2023-06-06	National Institute Of Biological Sciences, Beijing	MLKL inhibitors
WO2018157800A1 (en) *	2017-02-28	2018-09-07	National Institute Of Biological Sciences, Beijing	Mlkl inhibitors
PT3652176T (pt) *	2017-07-11	2022-01-13	Boehringer Ingelheim Int	Novos derivados de xantina substituídos
CA3093084A1 (en) *	2018-03-05	2019-09-12	Goldfinch Bio, Inc.	Imidazodiazepinediones and methods of use thereof
WO2020120450A1 (en) *	2018-12-12	2020-06-18	Boehringer Ingelheim International Gmbh	Substituted xanthine derivatives
US12291532B2 (en)	2018-12-12	2025-05-06	Boehringer Ingelheim International Gmbh	Substituted xanthines as modulators of TRPC5 activity
CN112979651B (zh) *	2021-04-09	2022-02-01	南京纽邦生物科技有限公司	一种副黄嘌呤的制备方法
CN113354646B (zh) *	2021-07-06	2022-11-15	南开大学	8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用
CN115636831B (zh) *	2022-10-27	2024-11-08	中国药科大学	稠合嘧啶二酮类化合物、其用途以及药物组合物
WO2024133476A1 (en)	2022-12-20	2024-06-27	Boehringer Ingelheim International Gmbh	Process for the preparation of 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione
WO2024153028A1 (zh) *	2023-01-20	2024-07-25	深圳晶蛋生物医药科技有限公司	大环类化合物、其药物组合物及其应用
WO2024165540A1 (en)	2023-02-06	2024-08-15	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione
CN118459461A (zh) *	2023-02-08	2024-08-09	中国科学院上海药物研究所	黄嘌呤类化合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4304650A1 (de) *	1993-02-16	1994-08-18	Thomae Gmbh Dr K	Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6878715B1 (en) *	1994-02-18	2005-04-12	Cell Therapeutics, Inc.	Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JP4191269B2 (ja)	1996-05-17	2008-12-03	興和株式会社	新規なアニリド化合物及びこれを含有する医薬
JPH10318487A (ja)	1997-05-16	1998-12-04	Mitsubishi Gas Chem Co Inc	真空断熱材用ゲッタ
US6075029A (en) *	1998-01-02	2000-06-13	Cell Therapeutics, Inc.	Xanthine modulators of metabolism of cellular P-450
US6187780B1 (en) *	1998-04-16	2001-02-13	Boehringer Ingelheim Pharma Kg	Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
DE60024604T2 (de) *	1999-04-09	2006-08-24	Cell Therapeutics, Inc., Seattle	Xanthinderivate und analoge als zellsignalisierung inhibitoren
DE60111849T2 (de) *	2000-07-04	2006-06-08	Novo Nordisk A/S	Purin-2,6-dione als inhibitoren des enzyms dipeptidyl-peptidase iv (dpp-iv)
HUP0400708A3 (en)	2000-12-07	2007-10-29	Cv Therapeutics	Substituted 1,3,5-triazine and pyrimidine derivatives, their use and pharmaceutical compositions containing them
ATE430749T1 (de) *	2001-02-24	2009-05-15	Boehringer Ingelheim Pharma	Xanthinderivate verwendung als arzneimittel sowie deren verfahren zur deren herstellung
MXPA04004388A (es) *	2001-11-09	2005-05-16	Cv Therapeutics Inc	Antagonistas del receptor a2b de adenosina.
DK1622908T3 (da) *	2003-05-06	2008-11-17	Cv Therapeutics Inc	Xanthin-derivater som A2B adenosin-receptor-antagonister
EP1691891A2 (en)	2003-11-13	2006-08-23	The Board Of Regents, The University Of Texas System	Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
US7393827B2 (en)	2004-12-30	2008-07-01	Diakine Therapeutics, Inc.	Pharmaceutical compositions and methods for restoring β-cell mass and function
US8143254B2 (en)	2005-02-18	2012-03-27	Cornell Research Foundation, Inc.	Methods for modulating ion channels
MX2008001931A (es) *	2005-08-10	2008-03-24	Smithkline Beecham Corp	Derivados de xantina como agonistas selectivos de hm74a.
CN101331126A (zh) *	2005-09-06	2008-12-24	史密丝克莱恩比彻姆公司	作为plk调节剂的苯并咪唑噻吩化合物
JP2009518333A (ja) *	2005-12-07	2009-05-07	ユセベファルマソシエテアノニム	キサンチン誘導体、その調製方法及びその使用
US7671061B2 (en) *	2005-12-22	2010-03-02	Hydra Biosciences, Inc.	Methods and compositions for treating pain
CN101405000A (zh)	2006-01-19	2009-04-08	艾博特公司	2-亚胺基-苯并咪唑化合物
WO2007101213A2 (en)	2006-02-28	2007-09-07	Kalypsys, Inc.	Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
US20090269313A1 (en) *	2006-07-19	2009-10-29	Diakine Therapeutics, Inc.	Encapsulation system
WO2009157938A1 (en) *	2008-06-26	2009-12-30	Cv Therapeutics, Inc.	A2b adenosine receptor antagonists for treating cancer
US20120148604A1 (en)	2009-08-20	2012-06-14	Transposagen Biopharmaceuticals, Inc.	Trp inhibitors and uses thereof
WO2011114184A1 (en) *	2010-03-15	2011-09-22	Glenmark Pharmaceuticals S.A.	Amides of heterocyclic compounds as trpa1 inhibitors
WO2012050641A2 (en)	2010-06-08	2012-04-19	Hydra Biosciences, Inc	Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
JP2013023102A (ja) *	2011-07-22	2013-02-04	Panasonic Corp	列車情報提供システム
AU2012294300A1 (en) *	2011-08-09	2014-03-20	Hydra Biosciences, Inc.	Inhibiting transient receptor potential ion channel TRPA1
CN103121970B (zh)	2012-12-04	2015-04-29	中国科学院昆明植物研究所	苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用
PE20151779A1 (es)	2013-03-15	2015-11-20	Hydra Biosciences Inc	Xantinas sustituidas y metodos de uso de las mismas

2014
- 2014-03-14 PE PE2015001829A patent/PE20151779A1/es active IP Right Grant
- 2014-03-14 EP EP14722452.1A patent/EP2970303B3/en active Active
- 2014-03-14 US US14/210,781 patent/US9359359B2/en active Active
- 2014-03-14 LT LTEP14722452.1T patent/LT2970303T/lt unknown
- 2014-03-14 TW TW103109651A patent/TWI609867B/zh active
- 2014-03-14 WO PCT/US2014/027920 patent/WO2014143799A2/en active Application Filing
- 2014-03-14 JP JP2016502662A patent/JP6360149B2/ja active Active
- 2014-03-14 KR KR1020157029667A patent/KR102227629B1/ko active Active
- 2014-03-14 CA CA2899646A patent/CA2899646C/en active Active
- 2014-03-14 CN CN201710063554.XA patent/CN107082782B/zh active Active
- 2014-03-14 DK DK14722452.1T patent/DK2970303T6/en active
- 2014-03-14 HR HRP20170840TT patent/HRP20170840T4/hr unknown
- 2014-03-14 SG SG11201506479TA patent/SG11201506479TA/en unknown
- 2014-03-14 MX MX2015011617A patent/MX370372B/es active IP Right Grant
- 2014-03-14 SI SI201430241T patent/SI2970303T1/sl unknown
- 2014-03-14 EA EA201591615A patent/EA028815B1/ru not_active IP Right Cessation
- 2014-03-14 PL PL14722452T patent/PL2970303T6/pl unknown
- 2014-03-14 UA UAA201507774A patent/UA117470C2/uk unknown
- 2014-03-14 AU AU2014228206A patent/AU2014228206C1/en active Active
- 2014-03-14 ES ES14722452.1T patent/ES2636835T7/es active Active
- 2014-03-14 MY MYPI2015702631A patent/MY189912A/en unknown
- 2014-03-14 CN CN201480023267.0A patent/CN105143229B/zh active Active
- 2014-03-14 NZ NZ711718A patent/NZ711718A/en unknown
- 2014-03-14 HU HUE14722452A patent/HUE033528T4/en unknown
- 2014-03-14 RS RS20170566A patent/RS56066B2/sr unknown
- 2014-03-14 PT PT147224521T patent/PT2970303T/pt unknown
- 2014-03-17 UY UY0001035488A patent/UY35488A/es active IP Right Grant
2015
- 2015-07-28 ZA ZA2015/05414A patent/ZA201505414B/en unknown
- 2015-07-29 IL IL240216A patent/IL240216B/en active IP Right Grant
- 2015-09-15 CL CL2015002738A patent/CL2015002738A1/es unknown
- 2015-09-15 PH PH12015502141A patent/PH12015502141B1/en unknown
2016
- 2016-04-25 US US15/137,327 patent/US20160237089A1/en not_active Abandoned
2017
- 2017-06-14 US US15/622,838 patent/US9969736B2/en active Active
- 2017-06-20 CY CY20171100647T patent/CY1119042T1/el unknown
2018
- 2018-05-02 US US15/968,941 patent/US10399982B2/en active Active
2019
- 2019-04-29 US US16/397,697 patent/US11208409B2/en active Active
2021
- 2021-11-10 US US17/523,838 patent/US11958854B2/en active Active
2024
- 2024-02-21 US US18/583,293 patent/US20250034143A1/en active Pending

Also Published As

Publication number	Publication date
CN107082782A (zh)	2017-08-22
EP2970303B1 (en)	2017-05-10
WO2014143799A4 (en)	2015-02-12
DK2970303T3 (en)	2017-06-26
PE20151779A1 (es)	2015-11-20
DK2970303T6 (en)	2018-10-08
MY189912A (en)	2022-03-21
UY35488A (es)	2014-10-31
TWI609867B (zh)	2018-01-01
PL2970303T6 (pl)	2018-12-31
NZ711718A (en)	2020-05-29
BR112015021164A2 (pt)	2017-07-18
AU2014228206C1 (en)	2018-10-25
CY1119042T1 (el)	2018-01-10
US20160237089A1 (en)	2016-08-18
EP2970303B9 (en)	2017-09-20
US20170305910A1 (en)	2017-10-26
EA028815B1 (ru)	2018-01-31
PH12015502141B1 (en)	2018-10-12
RS56066B1 (sr)	2017-10-31
KR20150133233A (ko)	2015-11-27
WO2014143799A9 (en)	2014-12-24
IL240216A0 (en)	2015-09-24
MX2015011617A (es)	2016-04-25
US11208409B2 (en)	2021-12-28
US20230040259A1 (en)	2023-02-09
CA2899646C (en)	2021-08-31
JP6360149B2 (ja)	2018-07-18
ZA201505414B (en)	2016-03-30
EP2970303A2 (en)	2016-01-20
US20140275071A1 (en)	2014-09-18
CL2015002738A1 (es)	2016-06-10
UA117470C2 (uk)	2018-08-10
IL240216B (en)	2018-11-29
BR112015021164A8 (pt)	2019-12-03
PT2970303T (pt)	2017-06-23
US20250034143A1 (en)	2025-01-30
LT2970303T (lt)	2017-07-25
US11958854B2 (en)	2024-04-16
DK2970303T5 (en)	2018-01-02
WO2014143799A2 (en)	2014-09-18
ES2636835T7 (es)	2018-11-20
HUE033528T4 (en)	2018-05-02
US9359359B2 (en)	2016-06-07
US9969736B2 (en)	2018-05-15
JP2016513717A (ja)	2016-05-16
ES2636835T3 (es)	2017-10-09
KR102227629B1 (ko)	2021-03-16
US20190322667A1 (en)	2019-10-24
EA201591615A1 (ru)	2016-05-31
US10399982B2 (en)	2019-09-03
WO2014143799A3 (en)	2014-11-06
AU2014228206A1 (en)	2015-09-24
RS56066B2 (sr)	2018-09-28
AU2014228206B2 (en)	2018-05-10
SI2970303T1 (sl)	2017-08-31
CA2899646A1 (en)	2014-09-18
HK1217329A1 (zh)	2017-01-06
EP2970303B3 (en)	2018-08-01
PL2970303T3 (pl)	2017-08-31
PH12015502141A1 (en)	2016-01-25
CN105143229B (zh)	2017-06-30
HRP20170840T4 (hr)	2018-11-16
TW201533044A (zh)	2015-09-01
US20180244674A1 (en)	2018-08-30
HUE033528T2 (hu)	2017-12-28
CN105143229A (zh)	2015-12-09
HRP20170840T1 (hr)	2017-09-08
MX370372B (es)	2019-12-11
CN107082782B (zh)	2020-03-20

Publication	Publication Date	Title
IL290547A (en)	2022-04-01	Antibodies and methods of use
IL280155A (en)	2021-03-01	Anti- SIGLEC-8 antibodies and methods of using them
IL240216B (en)	2018-11-29	Converted xanthines and methods of using them
IL245844A0 (en)	2016-08-02	Converted benzamides and methods of using them
GB2535360B (en)	2017-04-12	Methods of preparing polyhemiaminals and polyhexahydrotriazines
IL244495A0 (en)	2016-04-21	Anti-alpha-synuclein antibodies and methods of use
SG11201600707QA (en)	2016-02-26	Substituted aminopyrimidine compounds and methods of use
IL244643A0 (en)	2016-04-21	Anti-ly6e antibodies and methods of use
PT3470074T (pt)	2020-11-30	Probióticos
IL245272B (en)	2020-11-30	pif-transfected cells and methods of use
SG11201507389RA (en)	2015-10-29	Integration of hydro-dechlorination and hydro-regeneration